Serum testosterone is not a correlate of prostate cancer lymph node involvement, but does predict biochemical failure for lymph node positive disease

Jason F. Kelly, Alan Pollack, Gunar K. Zagars

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Previously we found that serum testosterone (serum-T) correlated with the development of distant metastasis in patients with clinically localized prostate cancer treated with radiotherapy. In this report, the relationship of serum-T to lymph node positivity and to patient outcome for patients with regional lymph node involvement treated with androgen ablation alone was investigated. Serum-T was available in 514 of 854 men with clinically localized prostate cancer who underwent pelvic lymphadenectomy at M.D. Anderson Cancer Center between 1984 and 1993. Pretreatment prostatic acid phosphatase (PAP) and prostate specific antigen (PSA) were assayed in 98% and 95% of patients, respectively. Androgen ablation was achieved via orchiectomy or a luteinizing hormone releasing hormone agonist. Median follow-up was 66 months for the node positive subgroup (n = 92). Serum-T did not correlate with palpable stage, Gleason score, pretreatment PSA, or lymph node involvement. Age ≤ 60 years and pretreatment PAP > 0.8 mU/ml correlated significantly with higher serum-T. In lymph node positive patients treated with androgen ablation, higher serum-T levels corresponded to both pretreatment PSA > 10 ng/ml and PAP > 0.8 mU/ml. Serum-T predicted for biochemical failure, but not metastatic relapse or overall survival. Actuarial 5-year biochemical failure rate was 73% for serum T > 500 ng/dl and 57% for serum-T ≤ 500 (p = 0.009). Multivariate analysis showed serum-T to be an independent correlate of rising PSA, both as a continuous (p = 0.001) or categorical (p = 0.037) variable. Serum-T did not significantly correlate with lymph node positivity, and therefore is not a marker for regional disease spread. However, serum-T was significantly associated with biochemical failure in node-positive patients treated with androgen ablation alone. Copyright (C) 1999 Elsevier Science Inc.

Original languageEnglish
Pages (from-to)78-84
Number of pages7
JournalUrologic Oncology
Volume5
Issue number2
DOIs
StatePublished - Mar 1 2000
Externally publishedYes

Fingerprint

Testosterone
Prostatic Neoplasms
Lymph Nodes
Serum
Prostate-Specific Antigen
Androgens
Orchiectomy
Neoplasm Grading
Lymph Node Excision
Gonadotropin-Releasing Hormone
Radiotherapy
Multivariate Analysis
Neoplasm Metastasis
Recurrence
Survival

Keywords

  • Androgen ablation
  • Lymphadenectomy
  • Prostate cancer
  • Testosterone

ASJC Scopus subject areas

  • Oncology
  • Urology

Cite this

Serum testosterone is not a correlate of prostate cancer lymph node involvement, but does predict biochemical failure for lymph node positive disease. / Kelly, Jason F.; Pollack, Alan; Zagars, Gunar K.

In: Urologic Oncology, Vol. 5, No. 2, 01.03.2000, p. 78-84.

Research output: Contribution to journalArticle

@article{76ff2a3c362244718fc33f8ce05cddbf,
title = "Serum testosterone is not a correlate of prostate cancer lymph node involvement, but does predict biochemical failure for lymph node positive disease",
abstract = "Previously we found that serum testosterone (serum-T) correlated with the development of distant metastasis in patients with clinically localized prostate cancer treated with radiotherapy. In this report, the relationship of serum-T to lymph node positivity and to patient outcome for patients with regional lymph node involvement treated with androgen ablation alone was investigated. Serum-T was available in 514 of 854 men with clinically localized prostate cancer who underwent pelvic lymphadenectomy at M.D. Anderson Cancer Center between 1984 and 1993. Pretreatment prostatic acid phosphatase (PAP) and prostate specific antigen (PSA) were assayed in 98{\%} and 95{\%} of patients, respectively. Androgen ablation was achieved via orchiectomy or a luteinizing hormone releasing hormone agonist. Median follow-up was 66 months for the node positive subgroup (n = 92). Serum-T did not correlate with palpable stage, Gleason score, pretreatment PSA, or lymph node involvement. Age ≤ 60 years and pretreatment PAP > 0.8 mU/ml correlated significantly with higher serum-T. In lymph node positive patients treated with androgen ablation, higher serum-T levels corresponded to both pretreatment PSA > 10 ng/ml and PAP > 0.8 mU/ml. Serum-T predicted for biochemical failure, but not metastatic relapse or overall survival. Actuarial 5-year biochemical failure rate was 73{\%} for serum T > 500 ng/dl and 57{\%} for serum-T ≤ 500 (p = 0.009). Multivariate analysis showed serum-T to be an independent correlate of rising PSA, both as a continuous (p = 0.001) or categorical (p = 0.037) variable. Serum-T did not significantly correlate with lymph node positivity, and therefore is not a marker for regional disease spread. However, serum-T was significantly associated with biochemical failure in node-positive patients treated with androgen ablation alone. Copyright (C) 1999 Elsevier Science Inc.",
keywords = "Androgen ablation, Lymphadenectomy, Prostate cancer, Testosterone",
author = "Kelly, {Jason F.} and Alan Pollack and Zagars, {Gunar K.}",
year = "2000",
month = "3",
day = "1",
doi = "10.1016/S1078-1439(99)00028-9",
language = "English",
volume = "5",
pages = "78--84",
journal = "Urologic Oncology: Seminars and Original Investigations",
issn = "1078-1439",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Serum testosterone is not a correlate of prostate cancer lymph node involvement, but does predict biochemical failure for lymph node positive disease

AU - Kelly, Jason F.

AU - Pollack, Alan

AU - Zagars, Gunar K.

PY - 2000/3/1

Y1 - 2000/3/1

N2 - Previously we found that serum testosterone (serum-T) correlated with the development of distant metastasis in patients with clinically localized prostate cancer treated with radiotherapy. In this report, the relationship of serum-T to lymph node positivity and to patient outcome for patients with regional lymph node involvement treated with androgen ablation alone was investigated. Serum-T was available in 514 of 854 men with clinically localized prostate cancer who underwent pelvic lymphadenectomy at M.D. Anderson Cancer Center between 1984 and 1993. Pretreatment prostatic acid phosphatase (PAP) and prostate specific antigen (PSA) were assayed in 98% and 95% of patients, respectively. Androgen ablation was achieved via orchiectomy or a luteinizing hormone releasing hormone agonist. Median follow-up was 66 months for the node positive subgroup (n = 92). Serum-T did not correlate with palpable stage, Gleason score, pretreatment PSA, or lymph node involvement. Age ≤ 60 years and pretreatment PAP > 0.8 mU/ml correlated significantly with higher serum-T. In lymph node positive patients treated with androgen ablation, higher serum-T levels corresponded to both pretreatment PSA > 10 ng/ml and PAP > 0.8 mU/ml. Serum-T predicted for biochemical failure, but not metastatic relapse or overall survival. Actuarial 5-year biochemical failure rate was 73% for serum T > 500 ng/dl and 57% for serum-T ≤ 500 (p = 0.009). Multivariate analysis showed serum-T to be an independent correlate of rising PSA, both as a continuous (p = 0.001) or categorical (p = 0.037) variable. Serum-T did not significantly correlate with lymph node positivity, and therefore is not a marker for regional disease spread. However, serum-T was significantly associated with biochemical failure in node-positive patients treated with androgen ablation alone. Copyright (C) 1999 Elsevier Science Inc.

AB - Previously we found that serum testosterone (serum-T) correlated with the development of distant metastasis in patients with clinically localized prostate cancer treated with radiotherapy. In this report, the relationship of serum-T to lymph node positivity and to patient outcome for patients with regional lymph node involvement treated with androgen ablation alone was investigated. Serum-T was available in 514 of 854 men with clinically localized prostate cancer who underwent pelvic lymphadenectomy at M.D. Anderson Cancer Center between 1984 and 1993. Pretreatment prostatic acid phosphatase (PAP) and prostate specific antigen (PSA) were assayed in 98% and 95% of patients, respectively. Androgen ablation was achieved via orchiectomy or a luteinizing hormone releasing hormone agonist. Median follow-up was 66 months for the node positive subgroup (n = 92). Serum-T did not correlate with palpable stage, Gleason score, pretreatment PSA, or lymph node involvement. Age ≤ 60 years and pretreatment PAP > 0.8 mU/ml correlated significantly with higher serum-T. In lymph node positive patients treated with androgen ablation, higher serum-T levels corresponded to both pretreatment PSA > 10 ng/ml and PAP > 0.8 mU/ml. Serum-T predicted for biochemical failure, but not metastatic relapse or overall survival. Actuarial 5-year biochemical failure rate was 73% for serum T > 500 ng/dl and 57% for serum-T ≤ 500 (p = 0.009). Multivariate analysis showed serum-T to be an independent correlate of rising PSA, both as a continuous (p = 0.001) or categorical (p = 0.037) variable. Serum-T did not significantly correlate with lymph node positivity, and therefore is not a marker for regional disease spread. However, serum-T was significantly associated with biochemical failure in node-positive patients treated with androgen ablation alone. Copyright (C) 1999 Elsevier Science Inc.

KW - Androgen ablation

KW - Lymphadenectomy

KW - Prostate cancer

KW - Testosterone

UR - http://www.scopus.com/inward/record.url?scp=0033991424&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033991424&partnerID=8YFLogxK

U2 - 10.1016/S1078-1439(99)00028-9

DO - 10.1016/S1078-1439(99)00028-9

M3 - Article

C2 - 21227292

AN - SCOPUS:0033991424

VL - 5

SP - 78

EP - 84

JO - Urologic Oncology: Seminars and Original Investigations

JF - Urologic Oncology: Seminars and Original Investigations

SN - 1078-1439

IS - 2

ER -